Renaissance Technologies LLC Has $1.82 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Renaissance Technologies LLC lowered its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,188,800 shares of the biotechnology company's stock after selling 819,398 shares during the quarter. Renaissance Technologies LLC owned about 0.78% of Heron Therapeutics worth $1,819,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in Heron Therapeutics by 295.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock worth $411,000 after purchasing an additional 154,487 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Heron Therapeutics by 456.5% in the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company's stock valued at $204,000 after buying an additional 84,205 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $208,000. Congress Park Capital LLC boosted its stake in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after buying an additional 477,417 shares during the period. Finally, Barclays PLC grew its position in Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock worth $434,000 after buying an additional 50,109 shares in the last quarter. Institutional investors own 80.01% of the company's stock.

Heron Therapeutics Price Performance

NASDAQ:HRTX traded up $0.04 during mid-day trading on Friday, reaching $2.39. The stock had a trading volume of 225,965 shares, compared to its average volume of 2,294,996. The stock has a 50-day simple moving average of $2.17 and a two-hundred day simple moving average of $1.80. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The stock has a market capitalization of $363.31 million, a PE ratio of -13.25 and a beta of 1.39.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to analyst estimates of $37.37 million. Equities analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HRTX. Needham & Company LLC reiterated a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.